How much weight did each retatrutide dose produce?

In the Phase 3 TRIUMPH-1 obesity trial at 80 weeks, mean body-weight reduction counting everyone randomized (the treatment-regimen estimand) was about 17.6% on 4 mg, 23.7% on 9 mg and 25.0% on 12 mg, versus 3.9% on placebo; among people who stayed on treatment it was 19.0%, 25.9% and 28.3%. About 45% of the 12 mg group reached 30% or more weight loss, and participants with higher baseline BMI who continued 12 mg to 104 weeks averaged roughly 30% (about 85 lb). In the earlier Phase 2 trial, 12 mg produced about 24.2% at 48 weeks.

Educational · Investigational compound

Retatrutide dosing & titration

Q: What is the retatrutide dose escalation schedule?

In the Phase 3 TRIUMPH-1 trial everyone started at 2 mg once weekly and stepped up every four weeks to an assigned target: 4 mg after one step, 9 mg via 4 and 6 mg, or 12 mg via 4, 6 and 9 mg. The earlier Phase 2 trial assigned targets of 1, 4, 8 or 12 mg, with some arms starting at 2 mg. Escalation is deliberately slow to limit gastrointestinal side effects. Retatrutide is investigational and not FDA-approved, so there is no official label schedule; these are trial protocols, not a prescription.

Q: Why is retatrutide titrated so slowly?

Like other incretin therapies, retatrutide's dose-limiting side effects are gastrointestinal – nausea, vomiting, diarrhea, and constipation – which are worst right after a dose increase. Slow, stepwise escalation lets the gut adapt and keeps most people on therapy. In the Phase 2 trial, starting at 2 mg rather than 4 mg partly reduced these effects. Pushing the dose faster than tolerance mostly buys more nausea, not more or faster weight loss.

Q: What is the maximum retatrutide dose?

The highest dose studied in the pivotal Phase 3 obesity trials is 12 mg once weekly, which also produced the largest weight loss. TRIUMPH-1 also randomized people to fixed targets of 4 mg and 9 mg, and Phase 2 tested 8 mg. There is no approved maximum because retatrutide is not yet approved.

Q: How do you reconstitute compounded retatrutide?

Compounded retatrutide is sold as a lyophilized powder in vials of varying strength (commonly 5, 10, 12, or 30 mg). You add a measured volume of bacteriostatic water to reach a known concentration, then draw the weekly dose on a U-100 insulin syringe. For example, a 10 mg vial reconstituted with 1 mL of bacteriostatic water gives 10 mg/mL, so a 2 mg dose is 0.2 mL (20 units). Concentrations vary by vial, so always compute from your own vial's stated strength – a reconstitution calculator does this arithmetic.

Retatrutide (Eli Lilly's LY3437943) is the triple-agonist injectable that produced the largest weight-loss numbers yet seen in obesity trials. This is a plain, evidence-graded look at how it was actually dosed in the Phase 3 TRIUMPH program – the weekly escalation, what each dose delivered, and why titration is paced by side effects. Retatrutide is investigational and not FDA-approved; this explains the trial protocols, it is not a prescription.

By OptiPin Editorial·Last updated July 2026

Trial escalation

2→4→6→9→12 mg

12 mg at 80 wk

~25% loss

Mechanism

Triple agonist

Dosing pace

Weekly, ~4-wk steps

TL;DR

• Escalation, not a fixed dose. TRIUMPH-1 started everyone at 2 mg and stepped up every four weeks toward an assigned target: 2 → 4 → 6 → 9 → 12 mg for the top dose.
• Dose tracks weight loss. At 80 weeks, counting everyone randomized: ~17.6% (4 mg), ~23.7% (9 mg), ~25.0% (12 mg) vs 3.9% placebo ^[2].
• Titration is GI-gated. Nausea peaks after each step-up; slow escalation is what keeps people on therapy.
• Glucagon is the third lever. Adding glucagon-receptor activity drives hepatic fat oxidation and energy expenditure on top of GLP-1/GIP.
• It is not approved. No label, no official maximum – the numbers here are trial data, and dosing decisions belong with a clinician.

What retatrutide is, in one paragraph

Retatrutide is a once-weekly injectable that activates three receptors at once: GLP-1 and GIP (the two that tirzepatide hits) plus the glucagon receptor. The GLP-1 and GIP arms suppress appetite and slow gastric emptying; the glucagon arm raises energy expenditure and pushes hepatic fat oxidation, which appears to be why the triple agonist reaches higher weight-loss ceilings than dual or single agonists ^[1]. The concurrent GLP-1/GIP activity offsets glucagon's tendency to raise blood sugar, so glycemic control held in the trials. It is developed by Eli Lilly and, as of 2026, is in Phase 3 – not yet approved.

The TRIUMPH dose-escalation schedule

The pivotal Phase 3 TRIUMPH program used a stepwise weekly escalation designed to reach a high maintenance dose slowly. The steps move up about every four weeks:

Step	Weekly dose	Typical window	Purpose
1	2 mg	~weeks 1–4	Introduction, gut adaptation
2	4 mg	~weeks 5–8	Target dose for the 4 mg arm
3	6 mg	~weeks 9–12	Build-up
4	9 mg	~weeks 13–16	Target dose for the 9 mg arm
5	12 mg	~week 17+	Target dose for the 12 mg arm

Two caveats. The earlier Phase 2 trial assigned targets of 1, 4, 8 or 12 mg, with some arms starting at 2 mg and others at 4 mg, which is why older references cite an "8 mg" step ^[1]. And not everyone in TRIUMPH-1 climbed to 12 mg: participants were randomized to a fixed target of 4, 9 or 12 mg, so the 4 mg arm stopped after one step and the 9 mg arm after three ^[2]. The week windows show the trial design, not a schedule to follow.

What each dose actually delivered

The dose-response is unusually clean, higher dose, more weight loss. From TRIUMPH-1 (obesity/overweight) at 80 weeks, counting everyone randomized whether or not they stayed on the drug (Lilly's treatment-regimen estimand) ^[2]^[3]. Among people who stayed on treatment the figures were 19.0%, 25.9% and 28.3%:

Dose	Mean weight loss (80 wk)	Notable
Placebo	~3.9%	Reference arm
4 mg	~17.6%	Smallest target, one step from 2 mg
9 mg	~23.7%	Target dose for the 9 mg arm
12 mg	~25.0%	~45% of this arm hit ≥30% loss

Longer and heavier: participants with a baseline BMI of 35+ who stayed on 12 mg through 104 weeks averaged about 30.3% (~85 lb) ^[3]. In the earlier Phase 2 read at 48 weeks, 12 mg produced about 24.2% ^[1]. For context, that Phase 2 figure edged out published tirzepatide data (~20–22%) in cross-trial comparison, which is the basis for retatrutide's "most powerful yet" framing, though no head-to-head trial has been completed. The comparison is covered in retatrutide vs tirzepatide.

Why titration is paced by side effects

Retatrutide's dose-limiting effects are gastrointestinal, nausea, vomiting, diarrhea, and constipation, and they are worst in the days right after a step-up. The entire point of the slow ladder is to let the gut adapt at each level before adding more. In the Phase 2 trial, these effects were partly reduced by starting at 2 mg rather than 4 mg ^[1]. The practical lesson runs counter to intuition: climbing faster than your tolerance does not buy faster weight loss, it mostly buys more nausea and a higher chance of quitting. Hold a step until it is comfortable; only then move up.

Reconstitution reality (compounded retatrutide)

Because retatrutide is not an approved finished product, people using it are typically reconstituting a lyophilized powder from a vial, commonly labeled 5, 10, 12, or 30 mg. The math is the same as any peptide: add a measured volume of bacteriostatic water to reach a known concentration, then draw the weekly dose on a U-100 insulin syringe. A 10 mg vial with 1 mL of bacteriostatic water is 10 mg/mL, so a 2 mg dose is 0.2 mL (20 units); a 6 mg dose is 0.6 mL (60 units). Vial strengths and fill volumes vary, so always compute from your own vial, our reconstitution calculator does it for you, and the sourcing-quality caveats in the US peptide FDA status page apply.

The honest part

Retatrutide is an investigational drug, not FDA-approved, and has no official dosing label. Every figure above is trial data presented for education, not a protocol to copy, and gray-market or research-use-only supply carries real concentration, purity, and sterility risk. Incretin therapies also carry contraindications and monitoring needs (including thyroid C-cell tumor warnings in the class and pancreatitis signals). Do not start, escalate, or source retatrutide based on this page – dosing is a decision for you and a licensed clinician.

Track your titration on one timeline

OptiPin logs each retatrutide dose, forecasts your level between shots from real PK curves, flags when a step-up is due, and tracks how much vial supply is left, with a daily side-effect check-in so you can see whether the last step-up has settled before the next. iOS, on-device.

Download OptiPin

Frequently asked questions

What is the retatrutide dose escalation schedule?

TRIUMPH-1 started everyone at 2 mg once weekly and stepped up every four weeks to an assigned target of 4, 9 or 12 mg (2 → 4 → 6 → 9 → 12 mg for the top dose). Phase 2 used targets of 1, 4, 8 and 12 mg. Escalation is slow to limit GI side effects. Retatrutide is not FDA-approved, so there is no official label schedule.

How much weight did each dose produce?

TRIUMPH-1 at 80 weeks, counting everyone randomized: about 17.6% (4 mg), 23.7% (9 mg) and 25.0% (12 mg) vs 3.9% placebo (19.0%, 25.9% and 28.3% among those who stayed on treatment); ~45% of the 12 mg arm reached ≥30% loss, and higher-BMI participants on 12 mg to 104 weeks averaged ~30% (~85 lb). Phase 2 showed ~24.2% at 48 weeks on 12 mg.

Why is retatrutide titrated so slowly?

Its dose-limiting side effects are gastrointestinal and peak right after each dose increase. Slow, stepwise escalation lets the gut adapt and keeps people on therapy; pushing faster than tolerance mostly adds nausea, not weight loss. In Phase 2, starting at 2 mg rather than 4 mg partly reduced them.

What is the maximum retatrutide dose?

12 mg once weekly is the highest dose in the pivotal Phase 3 obesity trials, and it produced the most weight loss. TRIUMPH-1 also tested fixed targets of 4 and 9 mg. There is no approved maximum because retatrutide is not yet approved.

How do you reconstitute compounded retatrutide?

Add a measured volume of bacteriostatic water to the powder vial to hit a known concentration, then draw on a U-100 syringe. A 10 mg vial + 1 mL water = 10 mg/mL, so 2 mg = 0.2 mL (20 units). Strengths vary; compute from your own vial with a reconstitution calculator.

Sources & further reading

Figures are from published Phase 2 and Phase 3 (TRIUMPH) results and vary by trial arm, population, and timepoint. Retatrutide is investigational; nothing here is a dosing recommendation.

Retatrutide side effects · Retatrutide reconstitution · Switching from tirzepatide · Retatrutide vs tirzepatide · Retatrutide + TRT · Retatrutide tracker · Retatrutide science · GLP-1 guide